Laura J. Hamill's most recent trade in Jazz Pharmaceuticals plc was a trade of 1,692 Ordinary Shares done at an average price of $241.4 . Disclosure was reported to the exchange on Aug. 31, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharma PLC | Laura J. Hamill | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 241.39 per share. | 31 Aug 2026 | 1,692 | 6,832 (0%) | 0% | 241.4 | 408,432 | Ordinary Shares |
| Jazz Pharma PLC | Laura J. Hamill | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.07 per share. | 31 Aug 2026 | 14 | 8,524 (0%) | 0% | 244.1 | 3,417 | Ordinary Shares |
| Jazz Pharma PLC | Laura J. Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2026 | 1,605 | 8,538 (0%) | 0% | 0 | Ordinary Shares | |
| Fate Therapeutics Inc | Laura J. Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2026 | 175,800 | 175,800 | - | - | Stock Option (Right to Buy) | |
| Jazz Pharma PLC | Laura J. Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 3,507 | 8,738 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Laura J. Hamill | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 111.25 per share. | 07 Aug 2025 | 1,805 | 6,933 (0%) | 0% | 111.3 | 200,807 | Ordinary Shares |
| Y-Mabs Therapeutics Inc | Laura J. Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 33,450 | 33,450 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Laura J. Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 25,080 | 30,905 (0%) | 0% | 0 | Common Stock | |
| Jazz Pharma PLC | Laura J. Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 3,731 | 5,231 (0%) | 0% | 0 | Ordinary Shares | |
| Y-Mabs Therapeutics Inc | Laura J. Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 14,545 | 14,545 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Laura J. Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 3,495 | 5,825 (0%) | 0% | 0 | Common Stock | |
| Scilex Holding Co | Laura J. Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2023 | 250,000 | 250,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| AnaptysBio Inc | Laura J. Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 10,600 | 10,600 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | Laura J. Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 3,900 | 3,900 | - | - | Restricted Stock Unit | |
| Y-Mabs Therapeutics Inc | Laura J. Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2022 | 16,000 | 16,000 | - | - | Non-Employee Stock Option (right to buy) | |
| AnaptysBio Inc | Laura J. Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 9,200 | 9,200 | - | - | Stock Option (right to buy) |